Sungwon Lim, Ph.D.
Douglas Thamm, VMD, DACVIM (O)
Kevin Choy, BSc, BVSc, MS, DACVIM (O)
Sue Ettinger, DVM, DACVIM (O)
Ilona Holcomb, Ph.D.
Oct 12, 2023 at 12pm
Peppermill Resort, Reno, Nevada
The session begins with a presentation from ImpriMed CEO and Co-Founder Dr. Sungwon Lim. Dr. Lim describes the history of product development at ImpriMed and new research on precision oncology. Dr. Lim's presentation is followed by a discussion with a panel of veterinary oncologists with experience using ImpriMed's AI-based Personalized Prediction Profile as a clinical support tool. Discussion is focused on clinical evidence of efficacy and practical examples of the use of ImpriMed's AI predictions in the clinic. ImpriMed's flagship product, the Personalized Prediction Profile, includes comprehensive diagnostic information and drug response predictions for canine blood cancers. Leveraging advanced artificial intelligence (AI) models trained on real-world clinical outcome data, ImpriMed predicts which anticancer drugs are most likely to be effective for a particular dog's lymphoma or leukemia. This prediction is based on comprehensive testing of each patient's live cancer cells and other relevant patient information.